Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on October 28, 2014, to report its third-quarter financial results for the period ending September 30, 2014. The primary purpose of this filing is to incorporate by reference the press release detailing these financial results, which was issued on the same day. Investors should refer to Exhibit 99.1, the attached press release, for specific details on revenue, earnings, and any forward-looking statements or business updates provided by the company for the quarter.
Key Highlights
- 1Vertex Pharmaceuticals reported its financial results for the third quarter ended September 30, 2014.
- 2The 8-K filing incorporates by reference a press release issued on October 28, 2014, containing the detailed financial results.
- 3Investors are directed to Exhibit 99.1 (the press release) for specific financial performance data.
- 4The filing does not contain new financial statements or exhibits beyond the press release.
- 5Information furnished in the press release is not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934, limiting liability for that specific content.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially report Vertex Pharmaceuticals' consolidated financial results for the third quarter ended September 30, 2014, by incorporating the press release that details these results.
The detailed financial results are provided in the press release dated October 28, 2014, which is attached as Exhibit 99.1 to this 8-K filing and is incorporated by reference.
No, this 8-K filing primarily includes the press release as Exhibit 99.1. It does not present new financial statements or other exhibits beyond this press release.
No, the information set forth in the press release (Exhibit 99.1) is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, meaning it is not subject to the same liability provisions as the 8-K filing itself, unless expressly incorporated into other filings.